Early history[ edit ] James O. Bower wanted to expand nationally and hire young business school graduates, whereas Kearney wanted to stay in Chicago and hire experienced accountants. McKinsey died after catching pneumonia.
Learn More Brii Biosciences is committed to bringing innovative medicines to China as a way to improve public health. We bring together clinically differentiated assets to meet this challenge, supported by world-class leadership, advisors, partners, and funders.
The pace of innovation has accelerated over the past decade, resulting in dramatically better treatments and cures for life-threatening diseases. Unfortunately, these innovations have not always reached China or the patients in China who need them.
Breakthroughs in science and technology, and advances in digital and data capabilities, are poised to disrupt the discovery, development and delivery of medicines. At the same time, the regulatory environment in China has improved significantly.
Leadership Team The Brii Bio leadership team includes industry-leading scientists with a strong track record of discovering and developing novel medicines. Prior to starting Brii Bio, Dr. GSK now has one of the most innovative pipelines against infectious diseases. Hong is a public health advocate who has helped establish multiple public-private partnerships with the U.
Hong started Ardea Biosciences later acquired by AstraZeneca. Hong has more than 25 years of experience in drug discovery and development and has brought more than 30 compounds into development, including many that have been approved and launched.
He is accountable for developing and driving execution of clinical development programs and registrations in China. Prior to joining the company, Dr. Yan was Vice President and Head Unit Physician of GSK Oncology, where he oversaw global development of oncology assets focusing on immunotherapy, cancer epigenetics, and cell therapy.
Prior to his tenure at GSK, he was Executive Director at Merck responsible for clinical development of oncology, respiratory and immunology, infectious diseases, and vaccines in emerging markets. He has published over 80 manuscripts and book chapters.
He is also an alumnus of the Harvard Business School enterprise executive program. Xu had an illustrious career at Gilead Sciences where she was a senior director, a co-inventor of several successful antiviral therapies, and led the discovery efforts in many therapeutic areas against HIV, HCV, HBV, and cancers resulting in numerous clinical candidates.
Prior to Gilead, Dr. Xu worked at Abbott Laboratories now AbbVie in the fields of anti-inflammatory and anti-cancer research. Xu holds a B. She has co-authored more than 30 peer-reviewed scientific publications and holds more than 30 issued patents and applications. Girardet served as Vice President, Pharmaceutical and Translational Sciences at Ardea Biosciences, a member of the AstraZeneca Group, where he led the progression of Ardea's internal discovery programs from concept to clinical development, and eventually to approval.
Girardet assisted the business development group in the sale of Ardea Biosciences to AstraZeneca, and in the successful licensing of refametinib to Bayer Healthcare. He supervised Ardea's GMP productions during clinical trials of refametinib, lesinurad, and verinurad. Girardet was Senior Director, Discovery Logistics, at Ardea Biosciences where he managed all of Ardea's drug substance GMP production and directed the intellectual property team to secure the company's assets.
Earlier in his career, Dr. He has co-authored more than 45 peer-reviewed publications and book chapters, and is an inventor on more than 30 U.
Zhu spent 10 years at MedImmune in the United States, where she served as the Director of Infectious Diseases and Vaccines with a particular focus in the fields of antiviral biologics and novel biotherapeutics.
Earlier in her career, Dr.
Zhu held positions of increasing responsibility at Chiron Corporation later Novartis Vaccines and Diagnostics developing vaccines and a small molecular inhibitor against the hepatitis C virus.
Zhu received her Ph. She completed her post-doctoral training in the virology program at Fox Chase Cancer Center. Lisa Beck Lisa Beck is Vice President of Business Development, with responsibility for transactions, alliance management, and strategy.
Beck has nearly 30 years of pharmaceutical and biotech experience across several therapeutic areas including infectious diseases, metabolic diseases, respiratory, dermatology, and rare diseases.
She has leadership experience in business development, portfolio management, corporate strategy, alliance management, project management, and clinical development. Prior to joining Brii Bio, Ms.
Prior to Alexion, she spent 26 years at GSK in roles spanning clinical development to project management, business development, and portfolio management. She has business development transactions experience across multiple therapeutic areas and led and executed well over 50 significant business transactions.
Beck received a B.Featured. McKinsey Academy Our learning programs help organizations accelerate growth by unlocking their people's potential. McKinsey & Co.: Managing Knowledge and Learning McKinsey & Co.: Managing Knowledge and Learning as it may reveal key case torosgazete.combes the development of McKinsey & Co.
as a worldwide. Describes the development of McKinsey & Co. as a worldwide management consulting firm from to In particular, it focuses on the way in which McKinsey has developed structures, systems, processes, and practices to help it develop, transfer, and disseminate knowledge among its 3, PDF | On Sep 5, , Dr.
Hesham Mohamed El-Sherif and others published McKinsey and Company Case Study Analysis. McKinsey & Company Managing Knowledge and Learning - Free download as PDF File .pdf), Text File .txt) or view presentation slides online.5/5(8). Knowledge Unplugged announces the results of a major survey of knowledge management practice within the most influential companies in the world, by the most influential management consultancy group in the world.
The McKinsey Knowledge Management team interviewed top executives and also investigated how far their plans were implemented in practice, in 40 companies in the US, Europe and .